Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$26.12 -1.8%	$29.27	$23.15 ▼ $91.99	$10.16B	1.83	10.86 million shs	6.59 million shs
OCGN Ocugen	$1.00 -0.2%	$1.03	$0.52 ▼ $1.40	$291.83M	3.84	4.63 million shs	2.06 million shs
PFE Pfizer	$24.57 +1.4%	$24.42	$20.92 ▼ $30.43	$139.69B	0.52	46.00 million shs	36.35 million shs
PHVS Pharvaris	$20.12 -1.0%	$19.13	$11.51 ▼ $26.33	$1.05B	-2.81	78,231 shs	123,961 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	-0.37%	-9.98%	-18.22%	+9.73%	-67.37%
OCGN Ocugen	+4.35%	-2.91%	-4.76%	+49.14%	-15.25%
PFE Pfizer	+1.24%	+4.19%	-5.33%	+8.82%	-15.93%
PHVS Pharvaris	-4.29%	+2.21%	+13.01%	+19.60%	+16.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRNA Moderna	4.3289 of 5 stars	4.0	1.0	0.0	4.6	2.9	2.5	0.6
OCGN Ocugen	1.7748 of 5 stars	3.5	2.0	0.0	0.0	3.1	0.0	0.0
PFE Pfizer	4.9867 of 5 stars	3.2	5.0	4.2	4.5	3.8	1.7	3.1
PHVS Pharvaris	1.7093 of 5 stars	3.5	2.0	0.0	0.0	2.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.04	Hold	$43.59	66.88% Upside
OCGN Ocugen	3.00	Buy	$6.00	500.96% Upside
PFE Pfizer	2.39	Hold	$28.12	14.44% Upside
PHVS Pharvaris	3.00	Buy	$36.20	79.92% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/4/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00
7/22/2025	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$26.00 ➝ $25.00
7/13/2025	MRNA Moderna	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$3.24B	3.14	N/A	N/A	$24.16 per share	1.08
OCGN Ocugen	$4.05M	72.06	N/A	N/A	$0.01 per share	99.84
PFE Pfizer	$63.83B	2.19	$4.48 per share	5.48	$15.66 per share	1.57
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	N/A
OCGN Ocugen	-$54.05M	-$0.20	N/A	N/A	N/A	-1,197.71%	-255.25%	-86.79%	N/A
PFE Pfizer	$8.03B	$1.88	13.07	8.11	0.87	16.84%	21.42%	9.12%	N/A
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)

Latest OCGN, MRNA, PFE, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	PHVS Pharvaris	-$0.87	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	$0.35 million	$1.37 million
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.00%	N/A	91.49%	16 Years
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A

Latest OCGN, MRNA, PFE, and PHVS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	N/A	3.93	3.77
OCGN Ocugen	9.18	1.83	2.60
PFE Pfizer	0.65	1.16	0.96
PHVS Pharvaris	N/A	11.10	11.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%
OCGN Ocugen	10.27%
PFE Pfizer	68.36%
PHVS Pharvaris	N/A

Insider Ownership

Company	Insider Ownership
MRNA Moderna	11.00%
OCGN Ocugen	4.42%
PFE Pfizer	0.06%
PHVS Pharvaris	11.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
OCGN Ocugen	80	292.30 million	279.39 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable

OCGN, MRNA, PFE, and PHVS Headlines

Recent News About These Companies

Pharvaris (PHVS) Projected to Post Earnings on Wednesday

August 6 at 4:39 AM | marketbeat.com

Analysts Set Pharvaris N.V. (NASDAQ:PHVS) PT at $36.20

August 5 at 2:59 AM | americanbankingnews.com

TD Asset Management Inc Has $1.23 Million Holdings in Pharvaris N.V. (NASDAQ:PHVS)

August 4, 2025 | marketbeat.com

Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Recommendation of "Buy" by Brokerages

July 31, 2025 | marketbeat.com

Pharvaris N.V.'s (NASDAQ:PHVS) 11% loss last week hit both individual investors who own 37% as well as institutions

July 27, 2025 | finance.yahoo.com

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Here's What Happened

July 26, 2025 | marketbeat.com

Pharvaris secures $175 million public offering

July 25, 2025 | thepharmaletter.comT

Pharvaris shares slide following $175 million equity offering

July 25, 2025 | msn.com

Pharvaris Raises $201 Million in Successful Offering

July 24, 2025 | tipranks.com

Pharvaris (NASDAQ:PHVS) Shares Gap Down - Here's What Happened

July 24, 2025 | marketbeat.com

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

July 22, 2025 | globenewswire.com

Pharvaris Announces Proposed Public Offering of Ordinary Shares

July 22, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Pharvaris (PHVS)

July 17, 2025 | theglobeandmail.com

Pharvaris (NASDAQ:PHVS) Stock Price Down 5.9% - Here's What Happened

July 15, 2025 | marketbeat.com

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?

July 14, 2025 | marketbeat.com

Bank of America Securities Reaffirms Their Sell Rating on Pharvaris (PHVS)

July 12, 2025 | theglobeandmail.com

Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High - Here's What Happened

July 12, 2025 | marketbeat.com

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 ...

July 11, 2025 | morningstar.comM

Pharvaris Updates Timing of Topline Data ... - The Manila Times

July 11, 2025 | manilatimes.netM

Pharvaris (NASDAQ:PHVS) Stock Price Up 9.9% - Time to Buy?

July 11, 2025 | marketbeat.com

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

July 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN, MRNA, PFE, and PHVS Company Descriptions

Moderna NASDAQ:MRNA

$26.12 -0.49 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$26.16 +0.04 (+0.13%)

As of 05:15 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen NASDAQ:OCGN

$1.00 0.00 (-0.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 -0.01 (-1.34%)

As of 05:16 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer NYSE:PFE

$24.57 +0.34 (+1.40%)

Closing price 03:59 PM Eastern

Extended Trading

$24.57 0.00 (0.00%)

As of 05:17 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pharvaris NASDAQ:PHVS

$20.12 -0.20 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$20.32 +0.20 (+0.99%)

As of 04:10 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time